All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Following the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the Lymphoma Hub spoke with John C. Byrd, OSUCCC −The James, Columbus, US. We asked, Is acalabrutinib superior to ibrutinib for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?
Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?
Byrd outlines data from the phase III ELEVATE-RR trial, a non-inferiority study which was the first to compare safety and overall survival between the BTK inhibitors acalabrutinib and ibrutinib, in patients with previously treated CLL.
Fixed-duration treatment with ibrutinib and venetoclax in patients with CLL/SLL: Findings from the GLOW and CAPTIVATE trials
Bruton’s tyrosine kinase inhibitors are a transformative therapeutic option for patients with high-risk chronic lymphocytic...
First results of a head-to-head trial of acalabrutinib versus ibrutinib in patients with high-risk CLL
Ibrutinib is a novel irreversible Bruton’s tyrosine kinase inhibitor (BTKi) approved for patients with chronic lymphocytic leukemia (CLL)/small...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox